If you want blockbuster sales, buy them in
An analysis of recent US drug sales confirms the growing role of licensing and acquisitions, though the biggest sellers conceal some interesting nuance.
EASL 2019 – Intercept and medics clash in Nash
Yesterday’s high-profile presentation of the Regenerate trial failed to quash concerns about Ocaliva in Nash, despite Intercept’s best attempts to polish the data.
AACR 2019 – Xospata meets the conditions of its US approval
Survival data confirm the value of Astellas’s FLT3-targeting approach in acute myelogenous leukaemia.
Should gene therapy patients be asked to pay?
The price in value-based payment deals should by definition be justified, so why is patient cost-sharing part of the calculation? Spark covers this cost, but there is no…
Events overtake Bavencio in ovarian cancer
Pfizer/Merck KGaA scrap a pivotal trial, partly because it tested Bavencio against what is no longer the relevant standard of care.
Bristol’s doomsday scenario: could Opdivo start shrinking next year?
Fears about flattening Opdivo sales were surely a major driver for Bristol's move for Celgene. To keep growing the checkpoint inhibitor needs some big clinical wins.
ACC 2019 preview – Amarin and Esperion look for an edge
Amarin and Esperion get a chance to reinforce their lipid-lowering candidates, while a Bayer heart failure project gets a high-profile slot despite its discontinuation.
ACC 2019 preview – Medtronic seeks guidelines change with Tyrx data
A positive readout for Medtronic's Tyrx envelope could mean an extra $1,000 per cardiac implant in the company's pocket.
Guardant’s liquid biopsy matches tissue testing in lung cancer
Guardant gets a liquid biopsy trial win, but if it wants to drive sales it must get cancer societies on board.
Kickstarting ideas
Independent, data-driven daily news and analysis on pharma, biotech and medtech.